

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

CD8 APC SK1 CE

RRID:AB_2868803

Type: Antibody

Proper Citation

BD Biosciences Cat# 345775, RRID:AB_2868803

Antibody Information

URL: http://antibodyregistry.org/AB_2868803

Proper Citation: BD Biosciences Cat# 345775, RRID:AB_2868803

Target Antigen: CD8

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD8 APC SK1 CE

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: SK1

Antibody ID: AB_2868803

Vendor: BD Biosciences

Catalog Number: 345775

Record Creation Time: 20250819T223658+0000

Record Last Update: 20250820T024555+0000

Ratings and Alerts

No rating or validation information has been found for CD8 APC SK1 CE.

No alerts have been found for CD8 APC SK1 CE.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Träger C, et al. (2025) A probiotic approach identifies a Treg-centred immunoregulation via modulation of gut microbiota metabolites in people with multiple sclerosis and healthy individuals. EBioMedicine, 116, 105743.

Munoz-Couselo E, et al. (2025) Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. Cancer research communications, 5(2), 358.

Tasis A, et al. (2024) Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with Azacitidine. Cancer research communications, 4(12), 3067.

Hansen AR, et al. (2024) Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(24), 5540.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer cell, 39(12), 1623.

Bonifacius A, et al. (2021) COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity, 54(2), 340.